An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
The study is being conducted to evaluate the efficacy, and safety of Lutetium (177Lu) Oxodotreotide Injection in Subjects With advanced gastrointestinal pancreatic neuroendocrine tumors.
Advanced Gastroenteropancreatic Neuroendocrine Tumor
DRUG: Lutetium (177Lu) Oxodotreotide Injectionï¼›long-acting Octreotide|DRUG: long-acting Octreotide.
Progression-free survival (PFS) assessed by BICR, up to 1 years follow-up
Overall Survival(OS), up to 5 years follow-up|Objective Response Rate(ORR), up to 1 years follow-up|Duration of Overall Response(DoR), up to 1 years follow-up|Disease Control Rate, up to 1 years follow-up|Incidence and severity of AE and SAE, up to 5 years follow-up
The study is being conducted to evaluate the efficacy, and safety of Lutetium (177Lu) Oxodotreotide Injection in Subjects With advanced gastrointestinal pancreatic neuroendocrine tumors.